Top

Published in:

01-11-2010 | Clinical Study - Patient Study

Prognostic value of pretreatment ¹⁸F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment

Authors: Nobuyuki Kawai, Hai-Ning Zhen, Keisuke Miyake, Yuka Yamamaoto, Yoshihiro Nishiyama, Takashi Tamiya

Published in: Journal of Neuro-Oncology | Issue 2/2010

Abstract

The purpose of this retrospective study was to evaluate the prognostic value of ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in immunocompetent patients with primary central nervous system lymphoma (PCNSL). We also investigated whether FDG uptake was related to angiogenesis in the tumors. Seventeen patients with newly diagnosed and histologically confirmed PCNSL were investigated with FDG-PET before the treatment. FDG uptake was assessed by standardized uptake value of the tumor showing the maximum uptake (SUV_max). The Kaplan–Meier method was used to estimate the overall and the progression-free survival times. The difference of the survival curves between the low to moderate FDG uptake (SUV_max < 12) and high FDG uptake (SUV_max ≥ 12) groups was statistically analyzed. The relationship between FDG SUV_max and microvessel density (MVD) in the tumor specimens determined by CD34 immunohistochemical staining was examined. Finally, the difference of the overall survival curve between the low MVD (<20) and high MVD (≥20) groups was statistically analyzed. After the completion of initial treatment, 7 of the 8 low to moderate FDG uptake patients showed complete response (CR) and 1 showed partial response (PR). On the other hand, 5 of the 9 high FDG uptake patients showed CR and 4 showed PR. However, the difference of treatment response (CR vs PR) between the low to moderate and high FDG uptake groups was not statistically significant (P = 0.36). Median survival time was more than 26 months in low to moderate FDG uptake patients and 12 months in high FDG uptake patients. The overall survival time of patients with low to moderate FDG uptake was significantly longer than that of patients with high FDG uptake (P < 0.05). The progression free survival (PFS) was also significantly longer in patients with low to moderate FDG uptake compared to the patients with high FDG uptake (P < 0.05). There was no significant relationship between FDG SUV_max and MVD in the tumors. The survival time tended to be longer in patients with high MVD than in low MVD, but the difference was not statistically significant (P = 0.15). Pretreatment FDG uptake may have a prognostic value in newly diagnosed PCNSL.

Calli C, Kitis O, Yunten N, Yurtseven T, Islekel S, Akalin T (2006) Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol 58:394–403CrossRefPubMed

Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L (2006) [¹¹C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. Am J Neuroradiol 27:1432–1437PubMed

Corry J, Smith JG, Wirth A, Quong G, Liew KH (1998) Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 41:615–620CrossRefPubMed

DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93–10. J Clin Oncol 20:4643–4648CrossRefPubMed

Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kufta CV, Kressler RM, Johnston GS, Manning RG, Wolf AP (1982) Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 32:1323–1329PubMed

Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell’Oro S, Zucca E, Cavalli F (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266–272CrossRefPubMed

Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570–4574CrossRefPubMed

Guha-Thakurta N, Damek D, Pollack C, Hochberg FH (1999) Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 43:259–268CrossRefPubMed

Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, Gaulard P, Garderet L, Lepage E, Reyes F, Meignan M (2005) [18f]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106:1376–1381CrossRefPubMed

10.

Haldorsen IS, Kråkenes J, Krossnes BK, Mella O, Espeland A (2009) CT and MRI imaging features of primary central nervous system lymphoma in Norway, 1989–2003. Am J Neuroradiol 30:744–751CrossRefPubMed

11.

Hartmann M, Heiland S, Harting I, Tronnier VM, Sommer C, Ludwig R, Sartor K (2003) Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett 338:119–122CrossRefPubMed

12.

Hatakeyama T, Kawai N, Nishiyama Y, Yamamoto Y, Sasakawa Y, Ichikawa T, Tamiya T (2008) ¹¹C-methionine (MET) and ¹⁸F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 35:2009–2017CrossRefPubMed

13.

Hayabuchi N, Shibamoto Y, Onizuka Y (1999) Primary central nervous system lymphoma in Japan: a nationwide survey. Int J Radiat Oncol Biol Phys 44:265–272PubMed

14.

Karantanis D, O’Neill BP, Subramaniam RM, Witte RJ, Mullan BP, Nathan MA, Lowe VJ, Peller PJ, Wiseman GA (2007) ¹⁸F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. Nucl Med Commun 28:834–841CrossRefPubMed

15.

Kawai N, Nishiyama Y, Miyake K, Tamiya T, Nagao S (2005) Evaluation of tumor FDG transport and metabolism in primary central nervous system lymphoma using [¹⁸F]fluorodeoxyglucose (FDG) positron emission tomography (PET) kinetic analysis. Ann Nucl Med 19:685–690CrossRefPubMed

16.

Kim S, Chung JK, Im SH, Jeong JM, Lee DS, Kim DG, Jung HW, Lee MC (2005) ¹¹C-methionine PET as a prognostic marker in patients with glioma: comparison with ¹⁸F-FDG PET. Eur J Nucl Med Mol Imaging 32:52–59CrossRefPubMed

17.

Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s Disease. J Nucl Med 43:1018–1027PubMed

18.

Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, Heiss WD (2003) Methyl-[11C]-L-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 30:868–873CrossRefPubMed

19.

Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T (1992) Intratumoral distribution of fluorine-18-fluorodeoxy glucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33:1972–1980PubMed

20.

Liao W, Liu Y, Wang X, Jiang X, Tang B, Fang J, Chen C, Hu Z (2009) Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast enhanced perfusion magnetic resonance imaging. Acta Radiol 50:217–225CrossRefPubMed

21.

Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, Paone G, Talbot JN, Rahmouni A, Meignan M (2007) Early ¹⁸F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-base assessment versus visual analysis. J Nucl Med 48:1626–1632CrossRefPubMed

22.

Mohile NA, DeAngelis LM, Abrey LE (2008) Utility of brain FDG-PET in primary CNS lymphoma. Clin Adv Hematol Oncol 6:818–820, 840

23.

Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, Thomson JW, Murray KJ (1992) Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23:9–17PubMed

24.

Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Kawai N, Satho K, Ohkawa M (2007) Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma. Eur J Nucl Med Mol Imaging 34:78–86CrossRefPubMed

25.

O’Brien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M, Olver I, Trotter G (2000) Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18:519–526PubMed

26.

O’Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS (1997) PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 38:1575–1583PubMed

27.

Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, Christian B, Ruppert J, Bernstein T, Kraus G, Mantil JC (2003) Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 64:227–237CrossRefPubMed

28.

Palmedo H, Urbach H, Bender H, Schlegel U, Schmidt-Wolf IG, Matthies A, Linnebank M, Joe A, Bucerius J, Biersack HJ, Pels H (2006) FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 33:164–168CrossRefPubMed

29.

Roelcke U, Leenders KL (1999) Positron emission tomography in patients with primary CNS lymphoma. J Neurooncol 43:231–236CrossRefPubMed

30.

Rosenfeld SS, Hoffman JM, Coleman RE, Glantz MJ, Hanson MW, Schold SC (1992) Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med 33:532–536PubMed

31.

Shibamoto Y, Ogino H, Suzuki G, Takemoto M, Araki N, Isobe K, Tsuchida E, Nakamura K, Kenjo M, Suzuki K, Hosono M, Tokumaru S, Ishihara S, Kato E, Ii N, Hayabuchi N (2008) Primary central nervous system lymphoma in Japan: changes in clinical features, treatment, and prognosis during 1985–2004. Neuro Oncol 10:560–568CrossRefPubMed

32.

Takeuchi H, Matsuda K, Kitai R, Sato K, Kubota T (2007) Angiogenesis in primary central nervous system lymphoma (PCNSL). J Neurooncol 84:141–145CrossRefPubMed

33.

Tateishi U, Nishihara H, Tsukamoto E, Morikawa T, Tamaki N, Miyasaka K (2002) Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism. J Comput Assist Tomogr 26:185–190CrossRefPubMed

34.

Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, Kobayashi M, Ouchi Y (2004) Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 31:22–28CrossRefPubMed

35.

Zhen HN, Zhang X, Hu PZ, Yang TT, Fei Z, Zhang JN, Fu LA, He XS, Ma FC, Wang XL (2005) Surviving expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer 104:2775–2783CrossRefPubMed

Title: Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment
Authors: Nobuyuki Kawai
Hai-Ning Zhen
Keisuke Miyake
Yuka Yamamaoto
Yoshihiro Nishiyama
Takashi Tamiya
Publication date: 01-11-2010
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2010
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-010-0182-0

At a glance: The STEP trials

Springer Medicine

Prognostic value of pretreatment ¹⁸F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Treatment-induced leukoencephalopathy in primary CNS lymphoma presenting as lower body parkinsonism

Rapid recurrence of craniopharyngioma following recombinant human growth hormone replacement

A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas

IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines

Epstein–Barr virus-associated primary central nervous system lymphomas in immunocompetent elderly patients: analysis for latent membrane protein-1 oncogene deletion and EBNA-2 strain typing

Inverse association of PPARγ agonists use and high grade glioma development